Imcd N.v. · EURONEXT:IMCD
Imcd — Merger or Acquisition (September 2020)
11 slides from Imcd's merger presentation, September 2020
Slide 1: IMCD Analyst Presentation September 2020
Page 1 IMCD Analyst Presentation September 2020
Slide 2: Strategic rationale for the Signet acquisition
Page 2 The acquisition of Signet by IMCD has a strong strategic rationale given their asset light business model and long-term relationships with leading global excipient producers. The acquisition is an important step in IMCD’s strategy to become a leading global speciality pharma ingredient distri
Slide 3: Signet overview
Page 3 Signet overview • Founded in 1986 • Headquartered in Mumbai, India • Active in India (~95% of sales), and adjacent markets i.e. Bangladesh, Middle East, and Africa • Focuses on the distribution of pharmaceutical, nutraceutical and bio-pharma excipients • Represents the world’s leading excipie
Slide 4: Transaction details
Page 4 Transaction details Transaction The transaction will take place in two tranches, with IMCD now acquiring 70% of structure the share capital from the founders at closing and the remaining 30% by 2024 Revenue LTM June 2020: INR 13.2 billion (ca. EUR 152 million) Key parameters EBITA LTM June 20
Slide 5: Signet investment highlights
Page 5 Signet investment highlights Signet is an excellent fit with IMCD • Strong presence in the distribution of pharmaceutical, nutraceutical and bio-pharma excipients in India • Present in India and the Middle East, one of the fastest growing regions in the space • Excellent management and staff
Slide 6: Strategic rationale
Page 6 Strategic rationale The acquisition of Signet by IMCD has a strong strategic rationale Strengthens IMCD’s footprint in the high growth and resilient pharma excipient Pharmaceuticals distribution market Asia-Pacific Increases geographic exposure to the high-growth Asia-Pacific region • Improve
Slide 7: IMCD's pharma strategy
Page 7 IMCD’s pharma strategy Over the past 10 months, IMCD made six acquisitions within the pharmaceutical ingredients space to strengthen its leadership position Entity Geography and coverage Sales Date Unired • Based in Colombia €7m 20 Nov. 2019 Quimicas • Active in pharma, focus on excipients •
Slide 8: IMCD's pharma strategy
Page 8 IMCD’s pharma strategy Pharma is a global market and the acquisition of Signet is an important step in IMCD’s ambition to become a global leading distributor of pharmaceutical ingredients 8 Comments • Total pharma business LTM June 2020 attributes to more than EUR 800 million1) • IMCD is pred
Slide 9: Summary
Page 9 Summary • It is an important step in IMCD’s strategy to become a leading global speciality pharma ingredient distributor. The acquisition of Signet: o Strengthens IMCD’s footprint in the high growth and resilient pharma excipient distribution market o Increases geographic exposure to the high
Slide 10: Our ambition is to exceed your expectations
Page 10 Our ambition is to exceed your expectations. We deliver what we promise. www.imcdgroup.com
Slide 11: Disclaimer
Page 11 DISCLAIMER – The content in this presentation is provided to you by IMCD N.V. (“IMCD”) and intended for your personal information only. All information appearing herein is based on our present knowledge and experience (“as is”) and IMCD makes no representations as to its accuracy or sufficie